Ardelyx Reports Q3 2026 Revenue Growth and Narrowing Net Loss
Ardelyx (ARDX) reported third-quarter product revenue of $125.5 million, driven by expanding patient adoption of its medicines. The company successfully narrowed its third-quarter net loss to $700,000 while maintaining high gross profit margins exceeding 95%. Management reaffirmed full-year IBSRELA revenue guidance in the range of $350 million to $370 million. Strategic developments include the early completion of patient enrollment for the Phase 3 ACCEL clinical trial, which evaluates IBSRELA for chronic idiopathic constipation (CIC). To support commercial growth and reduce administrative friction, Ardelyx has doubled its field reimbursement team to assist healthcare providers with prior authorization processes. The company remains focused on achieving full commercial profitability by 2027.
Tickers: $ARDX
Topics: clinical trial enrollment financial guidance product revenue quarterly earnings